Skip to content
Log in
Sponsored AI Networking Cookbook: Practical recipes for AI-assisted network automation and development AI Networking Cookbook: Practical recipes for AI-assisted network automation and development

Targeting CD38 with bispecific antibody XmAb 18968 in patients with relapsed/refractory acute myeloid leukemia and T-cell acute lymphoblastic leukemia.

G. S. Guru Murthy B. Shah Talha Badar Jessica T. Leonard A. Duvall Cecilia Y. Arana Yi A. Szabo Arielle Baim A. Harrington L. Runaas Karen Carlson Laura C. Michaelis S. Abedin Tyce J. Kearl E. Atallah
Sep 2026 · Leukemia · 0 citations · 26 references
Medicine

TL;DR

XmAb18968 is safe and tolerable with encouraging preliminary efficacy, supporting further investigation of CD38 targeting therapies in this setting, and further investigation of CD38 targeting therapies in this setting is supported.

DOI PubMed Semantic Scholar
View source

Similar papers

Open access Sep 2026

Bicistronic CD19/CD22 CAR T-Cell Therapy in Pediatric B-Cell Acute Lymphoblastic Leukemia: A Nonrandomized Clinical Trial.

In this nonrandomized clinical trial, bicistronic CD19/CD22 CAR T-cell therapy induced high rates of minimal residual disease-negative remission, with durable EFS in pediatric B-ALL, and support further evaluation in prospective trials.

Xinyu Wan, Yan-Jing Tang, Jiao-Yang Cai et al. · 1 citation
Sep 2026

Daratumumab in Combination With High-Dose Cytarabine and Amsacrine as an Effective Salvage Therapy and Bridge to Allogeneic Hematopoietic Stem Cell Transplantation for Refractory T-Cell Acute Lymphoblastic Leukemia: A Case Report.

The achievement of a third complete response with the combination of daratumumab, high-dose cytarabine, and amsacrine in an 11-year-old patient with highly aggressive relapsed T-ALL, enabling subsequent allogeneic hematopoietic stem cell transplantation.

Perrine Moyer, Baptiste Le Calvez, C. Mayeur-Rousse et al. · 0 citations
Open access Sep 2026

A Phase I/II Trial of Anti-CD22/CD19 CAR-T Cell Therapy, CART2219.1, in Adult and Pediatric Relapsed/Refractory B-ALL.

Exploratory multi-omic profiling linked durable response to higher CD22 antigen density on blasts; pre-infusion CD4 CAR-T cells expressing IL7Rα, LEF1, BACH2, and TCF7 but lower FOXP3; post-infusion NK-like effector CAR-T expansion; and central-memory CAR-T pool maintenance.

M. Seng, Ze-Xi Guo, Kai Soon Ng et al. · 1 citation
Open access Sep 2026

Outcomes of locally produced donor-derived anti-CD19 chimeric antigen receptor T-cells in relapsed or refractory B-cell acute lymphoblastic leukemia patients

Donor-derived anti-CD19 chimeric antigen receptor T-cell (CAR T-cell) therapy has emerged as one of the most promising treatments for relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). In this retrospective study, we evaluated the safety and efficacy of donor-derived anti-CD19 CAR T cells manufactur...

Supavich Tannumsaeng, U. Anurathapan, Arpatsorn Sermcheep et al. · 0 citations
Open access Sep 2026

Academic manufacturing of anti-CD19 CAR-T cells from a leukapheresis with a high proportion of acute myeloid leukaemia blasts.

This report describes the manufacturing of anti-CD19 chimeric antigen receptor-T (CAR-T) cells in an academic setting for a patient with a high tumour burden (>90%) who was referred for CD19+ acute myeloid leukaemia (AML). A 30-year-old woman with refractory acute myeloid leukaemia (AML) was found with 94% circulating...

Alexis Cuffel, A. Bisson, P. Ruminy et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.